scholarly journals A Systematic Review of Computational Drug Discovery, Development, and Repurposing for Ebola Virus Disease Treatment

Molecules ◽  
2017 ◽  
Vol 22 (10) ◽  
pp. 1777 ◽  
Author(s):  
James Schuler ◽  
Matthew Hudson ◽  
Diane Schwartz ◽  
Ram Samudrala
Keyword(s):  
Systematic Review ◽  
Drug Discovery ◽  
Ebola Virus ◽  
Virus Disease ◽  
Ebola Virus Disease ◽  
Disease Treatment ◽  
Computational Drug Discovery

scholarly journals Effects of vaccines in protecting against Ebola virus disease: protocol for a systematic review

BMJ Open ◽  
2019 ◽  
Vol 9 (7) ◽  
pp. e029617 ◽  
Author(s):  
Lindi Mathebula ◽  
Duduzile Edith Ndwandwe ◽  
Elizabeth Pienaar ◽  
Charles Shey Wiysonge
Keyword(s):  
Systematic Review ◽  
Ebola Virus ◽  
Virus Disease ◽  
Data Extraction ◽  
Case Fatality ◽  
Fixed Effect Model ◽  
Ebola Virus Disease ◽  
Pool Data ◽  
Cochrane Central Register ◽  
Clinical Trial Registry

IntroductionEbola virus disease is one of the most devastating infectious diseases in the world with up to 90% case fatality observed. There are at least 13 candidate vaccines developed and being tested to prevent the occurrence of the Ebola virus disease. While none of these candidate vaccines has received regulatory approval for use, one candidate vaccine (rVSVΔG-ZEBOV-GP) has been granted access for emergency use. Two other candidate vaccines (GamEvac-Combi and Ad5-EBOV) have been licensed for emergency use in their countries of origin. The objective of this systematic review is to summarise the effects of the Ebola candidate vaccines in humans.Methods and analysisWe will search for potentially eligible studies, with no language or date restrictions, in the Cochrane Central Register of Controlled Trials, PubMed, Scopus, the WHO International Clinical Trial Registry Platform, and reference lists of relevant publications. The Cochrane Database of Systematic Reviews (CDSR) and the Database of Abstracts of Reviews of Effect (DARE) will be searched for related reviews. Two review authors will independently screen search records, assess study eligibility, perform data extraction, and assess the risk of bias; and reconcile their findings. We will pool data from similar studies using Mantel-Haenszel’s fixed-effect model.Ethics and disseminationThis study is exempted from ethical consideration since the data collected are publicly available and at no point will confidential information from human participants be used. We will disseminate our results through publications in peer-reviewed journals and relevant conferences.PROSPERO registration numberCRD42018110505.

scholarly journals A systematic review and meta-analysis of patient data from the West Africa (2013–16) Ebola virus disease epidemic

2019 ◽  
Vol 25 (11) ◽  
pp. 1307-1314 ◽  
Author(s):  
A.M. Rojek ◽  
A. Salam ◽  
R.J. Ragotte ◽  
E. Liddiard ◽  
A. Elhussain ◽  
...  
Keyword(s):  
Systematic Review ◽  
West Africa ◽  
Ebola Virus ◽  
Virus Disease ◽  
Meta Analysis ◽  
Patient Data ◽  
Ebola Virus Disease ◽  
The West

Bacterial co-infection is rare in patients with Ebola virus disease in a military Ebola virus disease treatment unit in Sierra Leone

2015 ◽  
Vol 71 (3) ◽  
pp. 406-407 ◽  
Author(s):  
Lucy Lamb ◽  
Jack Robson ◽  
Christian Ardley ◽  
Mark Bailey ◽  
Stuart Dickson ◽  
...  
Keyword(s):  
Sierra Leone ◽  
Ebola Virus ◽  
Virus Disease ◽  
Ebola Virus Disease ◽  
Disease Treatment ◽  
Treatment Unit

scholarly journals A systematic review of early modelling studies of Ebola virus disease in West Africa – CORRIGENDUM

2017 ◽  
Vol 145 (9) ◽  
pp. 1961-1961
Author(s):  
Z. S. Y. WONG ◽  
C. M. BUI ◽  
A. A. CHUGHTAI ◽  
C. R. MACINTYRE
Keyword(s):  
Systematic Review ◽  
West Africa ◽  
Ebola Virus ◽  
Virus Disease ◽  
Ebola Virus Disease ◽  
Modelling Studies

scholarly journals Identification of novel Ebola virus inhibitors using biologically contained virus

2021 ◽  
Author(s):  
Bert Vanmechelen ◽  
Joren Stroobants ◽  
Winston Chiu ◽  
Joost Schepers ◽  
Arnaud Marchand ◽  
...  
Keyword(s):  
Small Molecule ◽  
Ebola Virus ◽  
Virus Disease ◽  
Treatment Options ◽  
Ebola Virus Disease ◽  
Disease Treatment ◽  
Pandemic Response ◽  
Screening Assays ◽  
Inhibitory Potential

Despite recent advancements in the development of vaccines and monoclonal antibody therapies for Ebola virus disease, treatment options remain limited. Moreover, management and containment of Ebola virus outbreaks is often hindered by the remote nature of the locations in which the outbreaks originate. Small-molecule compounds offer the advantage of being relatively cheap and easy to produce, transport and store, making them an interesting modality for the development of novel therapeutics against Ebola virus disease. Furthermore, the repurposing of small-molecule compounds, previously developed for alternative applications, can aid in reducing the time needed to bring potential therapeutics from bench to bedside. For this purpose, the Medicines for Malaria Venture provides collections of previously developed small-molecule compounds for screening against other infectious diseases. In this study, we used biologically contained Ebola virus to screen over 4,200 small-molecule drugs and drug-like compounds provided by the Medicines for Malaria Venture (i.e., the Pandemic Response Box and the COVID Box) and the Centre for Drug Design and Discovery (CD3, KU Leuven, Belgium). In addition to confirming known Ebola virus inhibitors, illustrating the validity of our screening assays, we identified eight novel selective Ebola virus inhibitors. Although the inhibitory potential of these compounds remains to be validated in vivo, they represent interesting compounds for the study of potential interventions against Ebola virus disease and might serve as a basis for the development of new therapeutics.

Sign in / Sign up

Export Citation Format

Share Document